Hikma Pharmaceuticals USA, Inc. FDA Inspection Record
Hikma Pharmaceuticals USA, Inc. is an FDA-inspected facility (FEI 2250102) located in Eatontown, NJ, US. RegDataLab tracks 13 FDA inspections and 1 compliance action at this facility.
What FDA found at this site
- Latest inspection
- Feb 1, 2019: No Action Indicated (NAI)
- Inspections on record
- 13 (2 OAI, 5 VAI, 6 NAI)
- Last OAI inspection
- Jun 7, 2013
- Warning letters
- 1 listed by FDA for this FEI, latest Feb 6, 2012
- Recalls as the recalling firm
- 42, latest Nov 6, 2017
- Import refusals
- 4
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Feb 1, 2019 | No Action Indicated (NAI) | No citations listed |
| Apr 13, 2018 | No Action Indicated (NAI) | No citations listed |
| Jul 7, 2016 | No Action Indicated (NAI) | No citations listed |
| Sep 10, 2015 | No Action Indicated (NAI) | No citations listed |
| Feb 26, 2014 | Voluntary Action Indicated (VAI) | Extent of discrepancy, failure investigations (21 CFR 211.192) |
| Jun 7, 2013 | Official Action Indicated (OAI) | No citations listed |
| Aug 28, 2012 | No Action Indicated (NAI) | No citations listed |
| Jun 30, 2011 | Official Action Indicated (OAI) | Equipment Design, Size and Location (21 CFR 211.63) Written procedures not established/followed (21 CFR 211.67(b)) Absence of Written Procedures (21 CFR 211.100(a)) Establishment of time limitations (21 CFR 211.111) and 6 more |
| Mar 25, 2011 | Voluntary Action Indicated (VAI) | Failure to review ADE information (21 CFR 314.80(b)) |
| Feb 17, 2011 | Voluntary Action Indicated (VAI) | Labeling and packaging improperly approved/released (21 CFR 211.122(b)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Nov 6, 2017 | Class III | D-0093-2018 | Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01)… and 1 more product Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). |
| Nov 17, 2016 | Class III | D-0172-2017 | SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTION, 62.5mg elemental iron/5mL, 10 (5mL… Subpotent Drug: Product has an an out of specification in iron assay analysis found during 18 month stability testing. |
| Nov 4, 2016 | Class III | D-0147-2017 | Amoxicillin for Oral suspension, USP 400 mg/5 mL, 100 mL (when reconstituted), Rx only… Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed. |
| Oct 3, 2016 | Class II | D-1045-2017 | Phenobarbital Tablets, USP 60mg 100=count bottles, Rx Only, Mfd. by: West-Ward… Failed Dissolution Specifications: Phenobarbital Tablets have an out of specification for dissolution at the 12 month stability time point |
| Aug 18, 2016 | Class III | D-1515-2016 | Amoxicillin For Oral Suspension, USP - Dye Free, 400 mg/5 mL, 100 mL (when reconstituted)… Labeling: Label Error on Declared Strength- bottles missing colored coded panel where strength of the product is displayed. |
| May 13, 2015 | Class III | D-1139-2015 | Fentanyl Citrate Inj., USP, CII, 250 mcg/5 mL (50 mcg/mL) (0.05 mg/mL), Rx Only, For IV or… Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548). |
| Oct 2, 2014 | Class II | D-0172-2015 | VERSAPHARM INCORPORATED Ethambutol Hydrochloride Tablets, USP, 100 mg, 100-count bottle… Subpotency: Out of Specification (OOS) result at the 36 month routine stability time point. |
| May 20, 2014 | Class II | D-1414-2014 | Isoniazid Tablets, USP, 300 mg, Rx only, packaged in a) 100-count bottles, NDC… Failed Dissolution Specifications: Stability lots cannot support dissolution past the 36 month time point. |
| Nov 7, 2013 | Class II | D-367-2014 | Carisoprodol Tablets, USP 350 mg, Rx Only, 1000 tablets. Dist by: West-ward… Presence of Foreign Substance; heavy metals (chromium, titanium etc) and inactive components of the product were visually observed during… |
| Sep 23, 2013 | Class II | D-66447-001 | Irinotecan Hydrochloride Injection, 40 mg/2 mL (20 mg/mL), 1 x 2 mL Single Dose Vial per… and 1 more product Superpotent Drug: a recent review of the USP revealed that an incorrect calculation was used to determine the amount of irinotecan to use in… |
FDA record score
0 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
37 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class II recall D-1045-2017, this FEI as the recalling firm | Oct 3, 2016 | 10 years or older, so it adds no points | 0 |
| Class II recall D-0172-2015, this FEI as the recalling firm | Oct 2, 2014 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1414-2014, this FEI as the recalling firm | May 20, 2014 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 26, 2014 | 10 years or older, so it adds no points | 0 |
| Class II recall D-367-2014, this FEI as the recalling firm | Nov 7, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-66447-001, this FEI as the recalling firm | Sep 23, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-853-2013, this FEI as the recalling firm | Jul 30, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-883-2013, this FEI as the recalling firm | Jul 30, 2013 | 10 years or older, so it adds no points | 0 |
| Inspection classified OAI | Jun 7, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-839-2013, this FEI as the recalling firm | Jun 4, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-824-2013, this FEI as the recalling firm | May 16, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-242-2013, this FEI as the recalling firm | Mar 18, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-306-2013, this FEI as the recalling firm | Mar 18, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-220-2013, this FEI as the recalling firm | Feb 6, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-170-2013, this FEI as the recalling firm | Jan 7, 2013 | 10 years or older, so it adds no points | 0 |
| Class II recall D-130-2013, this FEI as the recalling firm | Dec 7, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-150-2013, this FEI as the recalling firm | Dec 7, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-133-2013, this FEI as the recalling firm | Dec 5, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-149-2013, this FEI as the recalling firm | Dec 5, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-174-2013, this FEI as the recalling firm | Dec 4, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-132-2013, this FEI as the recalling firm | Nov 30, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-189-2013, this FEI as the recalling firm | Nov 30, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1437-2012, this FEI as the recalling firm | Apr 13, 2012 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Feb 6, 2012 | 10 years or older, so it adds no points | 0 |
| Class II recall D-1276-2012, this FEI as the recalling firm | Jan 24, 2012 | 10 years or older, so it adds no points | 0 |
| Inspection classified OAI | Jun 30, 2011 | 10 years or older, so it adds no points | 0 |
| Class II recall D-223-2012, this FEI as the recalling firm | May 19, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Mar 25, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 17, 2011 | 10 years or older, so it adds no points | 0 |
| Class II recall D-280-2011, this FEI as the recalling firm | Jan 25, 2011 | 10 years or older, so it adds no points | 0 |
| Class II recall D-884-2010, this FEI as the recalling firm | Jun 4, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Jun 1, 2010 | 10 years or older, so it adds no points | 0 |
| Class II recall D-494-2010, this FEI as the recalling firm | Mar 9, 2010 | 10 years or older, so it adds no points | 0 |
| Class II recall D-370-2010, this FEI as the recalling firm | Jan 8, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | May 19, 2009 | 10 years or older, so it adds no points | 0 |
| Class II recall D-200-2009, this FEI as the recalling firm | Jan 14, 2009 | 10 years or older, so it adds no points | 0 |
| Class II recall D-237-6, this FEI as the recalling firm | Mar 23, 2006 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Hikma Pharmaceuticals USA, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Hikma Pharmaceuticals USA, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Hikma Pharmaceuticals USA, Inc.
- Location
- Eatontown, NJ (US)
- Source
- inspections